{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:29:54Z","timestamp":1793406594561,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-55072-0","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T01:35:12Z","timestamp":1779759312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of community pharmacists\u2019 knowledge on rivaroxaban drug and food interactions in Sudan"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5919-0302","authenticated-orcid":false,"given":"Abdulkarim","family":"Dakah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodaina","family":"Abdalraheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawasul","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anfal","family":"Abdalshakor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mozdalfa","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"55072_CR1","doi-asserted-by":"crossref","unstructured":"Alexander, P. et al. Current trends in the duration of anticoagulant therapy for venous thromboembolism: A systematic review. Cureus. 13(10), e18992 (2021).","DOI":"10.7759\/cureus.18992"},{"issue":"11","key":"55072_CR2","doi-asserted-by":"publisher","first-page":"6585","DOI":"10.1097\/MS9.0000000000002589","volume":"86","author":"Z Qureshi","year":"2024","unstructured":"Qureshi, Z., Altaf, F., Jamil, A., Siddique, R. & Shah, S. Breaking boundaries: exploring recent advances in anticoagulation and thrombosis management: a comprehensive review. Ann. Med. Surg. 86 (11), 6585\u20136597 (2024).","journal-title":"Annals Med. Surg."},{"key":"55072_CR3","doi-asserted-by":"crossref","unstructured":"Tadesse, T. A. et al. Challenges of anticoagulation management service and need of establishing pharmacist-led anticoagulation clinic in tertiary care teaching hospital, Ethiopia: a qualitative study. J. Multidiscip. Healthc. 743\u2013754 (2022).","DOI":"10.2147\/JMDH.S359558"},{"key":"55072_CR4","unstructured":"Richards, P. A study of the impact of substituting Warfarin with Direct Oral Anticoagulants (DOAC), in Atrial Fibrillation (AF) patients over 65 years old: The Patients\u2019 and Clinicians\u2019 Perspectives (Doctoral dissertation, University of Westminster, 2020)."},{"issue":"6","key":"55072_CR5","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1007\/s11096-017-0551-2","volume":"39","author":"J Papastergiou","year":"2017","unstructured":"Papastergiou, J. et al. Pharmacists\u2019 confidence when providing pharmaceutical care on anticoagulants, a multinational survey. Int. J. Clin. Pharm. 39 (6), 1282\u20131290 (2017).","journal-title":"Int. J. Clin. Pharm."},{"key":"55072_CR6","doi-asserted-by":"crossref","unstructured":"Basilim, A. Assessing the knowledge and awareness of community pharmacists toward direct oral anticoagulant therapy in Saudi Arabia: A cross-sectional study. Medicine, 104(40), e44977. (2025).","DOI":"10.1097\/MD.0000000000044977"},{"issue":"8","key":"55072_CR7","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/jcph.1838","volume":"61","author":"V Ashton","year":"2021","unstructured":"Ashton, V., Kerolus-Georgi, S. & Moore, K. T. The pharmacology, efficacy, and safety of rivaroxaban in renally impaired patient populations. J. Clin. Pharmacol. 61 (8), 1010\u20131026 (2021).","journal-title":"J. Clin. Pharmacol."},{"issue":"6","key":"55072_CR8","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/jth.12973","volume":"13","author":"J Beyer-Westendorf","year":"2015","unstructured":"Beyer-Westendorf, J. & Siegert, G. Of men and meals. J. Thromb. Haemost. 13 (6), 943\u2013945 (2015).","journal-title":"J. Thromb. Haemost."},{"issue":"12","key":"55072_CR9","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/jcph.958","volume":"57","author":"L Zhang","year":"2017","unstructured":"Zhang, L. et al. A cross-study analysis evaluating the effects of food on the pharmacokinetics of rivaroxaban in clinical studies. J. Clin. Pharmacol. 57 (12), 1607\u20131615 (2017).","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"55072_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/cpdd.1330","volume":"13","author":"X Sun","year":"2024","unstructured":"Sun, X. et al. Effect of a high-fat diet on the pharmacokinetics and safety of rivaroxaban in healthy Chinese subjects. Clin. Pharmacol. Drug Dev. 13 (2), 146\u2013151 (2024).","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"1","key":"55072_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1365-2125.2012.04181.x","volume":"74","author":"XS Xu","year":"2012","unstructured":"Xu, X. S. et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. Br. J. Clin. Pharmacol. 74 (1), 86\u201397 (2012).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"55072_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","volume":"53","author":"W Mueck","year":"2014","unstructured":"Mueck, W. et al. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin. Pharmacokinet. 53, 1\u201316. https:\/\/doi.org\/10.1007\/s40262-013-0100-7 (2014).","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"55072_CR13","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3390\/jpm11040250","volume":"11","author":"S Fernandez","year":"2021","unstructured":"Fernandez, S. et al. Drug-drug interactions leading to adverse drug reactions with rivaroxaban: A systematic review of the literature and analysis of VigiBase. J. Personalized Med. 11 (4), 250 (2021).","journal-title":"J. Personalized Med."},{"key":"55072_CR14","doi-asserted-by":"publisher","unstructured":"Gackowski, M. et al. Novel thiourea and oxime ether isosteviol-based anticoagulants: MD simulation and ADMET prediction. Pharmaceuticals. 17(2), 163. https:\/\/doi.org\/10.3390\/ph17020163 (2024).","DOI":"10.3390\/ph17020163"},{"key":"55072_CR15","doi-asserted-by":"publisher","first-page":"7027","DOI":"10.1007\/s11696-023-02994-y","volume":"77","author":"M Gackowski","year":"2023","unstructured":"Gackowski, M., Madriwala, B. & Koba, M. In silico design, docking simulation, and ANN-QSAR model for predicting the anticoagulant activity of thiourea isosteviol compounds as FXa inhibitors. Chem. Pap. 77, 7027\u20137044. https:\/\/doi.org\/10.1007\/s11696-023-02994-y (2023).","journal-title":"Chem. Pap"},{"issue":"13","key":"55072_CR16","doi-asserted-by":"publisher","first-page":"4977","DOI":"10.3390\/molecules28134977","volume":"28","author":"M Gackowski","year":"2023","unstructured":"Gackowski, M., Madriwala, B., Studzi\u0144ska, R. & Koba, M. Novel isosteviol-based FXa inhibitors: molecular modeling. Silico Des. Docking Simul. Molec. . 28 (13), 4977. https:\/\/doi.org\/10.3390\/molecules28134977 (2023).","journal-title":"Silico Des. Docking Simul. Molecules"},{"issue":"12","key":"55072_CR17","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/jcph.958","volume":"57","author":"L Zhang","year":"2017","unstructured":"Zhang, L. et al. A cross-study analysis evaluating the effects of food on the pharmacokinetics of rivaroxaban in clinical studies. J. Clin. Pharmacol. 57 (12), 1607\u20131615. https:\/\/doi.org\/10.1002\/jcph.958 (2017).","journal-title":"J. Clin. Pharmacol."},{"issue":"16","key":"55072_CR18","doi-asserted-by":"publisher","first-page":"8531","DOI":"10.3390\/ijms22168531","volume":"22","author":"G Grze\u015bk","year":"2021","unstructured":"Grze\u015bk, G. et al. The clinical significance of drug\u2013food interactions of direct oral anticoagulants. Int. J. Mol. Sci. 22 (16), 8531 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"55072_CR19","doi-asserted-by":"publisher","first-page":"787235","DOI":"10.3389\/fcvm.2021.787235","volume":"8","author":"A Sanchez-Fuentes","year":"2022","unstructured":"Sanchez-Fuentes, A., Rivera-Caravaca, J. M., Lopez-Galvez, R., Marin, F. & Roldan, V. Non-vitamin K antagonist oral anticoagulants and drug-food interactions: implications for clinical practice and potential role of probiotics and prebiotics. Front. Cardiovasc. Med. 8, 787235 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"55072_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.12927\/hcq.2009.21101","volume":"13","author":"C Jones","year":"2009","unstructured":"Jones, C. & Lacombe, G. Enhancing patient care via a pharmacist-managed rural anticoagulation clinic. Healthc. Q. 13, 69\u201374 (2009).","journal-title":"Healthc. Q."},{"issue":"1","key":"55072_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.56782\/pps.307","volume":"23","author":"PV Chaudhari","year":"2025","unstructured":"Chaudhari, P. V. et al. A comprehensive review on drug-induced diseases and teratogenicity. Prospects Pharm. Sci. 23 (1), 66\u201373. https:\/\/doi.org\/10.56782\/pps.307 (2025).","journal-title":"Prospects Pharm. Sci."},{"issue":"1","key":"55072_CR22","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11239-017-1585-y","volume":"45","author":"S Piran","year":"2018","unstructured":"Piran, S., Schulman, S., Panju, M. & Pai, M. Oral anticoagulant dosing, administration, and storage: a cross-sectional survey of Canadian health care providers. J. Thromb. Thrombolysis. 45 (1), 180\u2013185 (2018).","journal-title":"J. Thromb. Thrombolysis"},{"issue":"6","key":"55072_CR23","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1177\/10600280211045075","volume":"56","author":"O Egunsola","year":"2022","unstructured":"Egunsola, O. et al. A qualitative systematic review of facilitators of and barriers to community pharmacists\u2013led anticoagulation management service. Ann. Pharmacother. 56 (6), 704\u2013715 (2022).","journal-title":"Ann. Pharmacother."},{"issue":"5","key":"55072_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/pharmacy12050134","volume":"12","author":"S Parekh","year":"2024","unstructured":"Parekh, S., Xu, L. & Livingstone, C. An evaluation of oral anticoagulant safety indicators by England\u2019s community pharmacies. Pharmacy 12 (5), 134 (2024).","journal-title":"Pharmacy"},{"key":"55072_CR25","doi-asserted-by":"publisher","first-page":"107602962093394","DOI":"10.1177\/1076029620933946","volume":"26","author":"A El-Bardissy","year":"2020","unstructured":"El-Bardissy, A. et al. Assessing pharmacists knowledge and attitude toward the direct oral anticoagulants in Qatar. Clin. Appl. Thromb. Hemost. 26, 1076029620933946 (2020).","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"55072_CR26","unstructured":"England, N. H. S. Community pharmacy oral anticoagulant safety audit 2021\/22 (2023)."},{"key":"55072_CR27","doi-asserted-by":"crossref","unstructured":"Vakili, Z., Heydarpour, F. & Shahbazi, F. Survey of knowledge and attitude of pharmacists about direct Oral anticoagulants: a cross-sectional study. J. Pharmaceut. Care. (2021).","DOI":"10.18502\/jpc.v9i3.7369"},{"key":"55072_CR28","doi-asserted-by":"crossref","unstructured":"Zawiah, M., Yousef, A. M., Khan, A. H., Al-Ashwal, F. Y., Matar, A., ALKhawaldeh,B., Abdo Ahmed, A. A. Food-drug interactions: Knowledge among pharmacists in Jordan. PloS one. 15(6), e0234779 (2020).","DOI":"10.1371\/journal.pone.0234779"},{"issue":"3","key":"55072_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.56782\/pps.199","volume":"22","author":"D \u0141aszczych","year":"2024","unstructured":"\u0141aszczych, D., Czernicka, A. & K\u0119dziora-Kornatowska, K. Interaction between warfarin and selected superfoods: a comprehensive review of potential mechanisms and their clinical significance. Prospects Pharm. Sci. 22 (3), 27\u201334. https:\/\/doi.org\/10.56782\/pps.199 (2024).","journal-title":"Prospects Pharm. Sci."},{"issue":"17","key":"55072_CR30","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.3390\/nu14173521","volume":"14","author":"M Gackowski","year":"2022","unstructured":"Gackowski, M., Szewczyk-Golec, K., M\u0105dra-Gackowska, K., Pluskota, R. & Koba, M. Quantitative structure\u2013activity relationship analysis of isosteviol-related compounds as activated coagulation factor X (FXa). Inhibit. Nutrients. 14 (17), 3521. https:\/\/doi.org\/10.3390\/nu14173521 (2022).","journal-title":"Inhibitors Nutrients"},{"issue":"12","key":"55072_CR31","doi-asserted-by":"publisher","first-page":"982","DOI":"10.2174\/1389201019666181112100612","volume":"19","author":"A Raiola","year":"2018","unstructured":"Raiola, A. et al. In vitro bioaccessibility, bioavailability, and plasma protein interaction of new oral anticoagulants in the presence of macronutrients. Curr. Pharm. Biotechnol. 19 (12), 982\u2013989 (2018).","journal-title":"Curr. Pharm. Biotechnol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55072-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55072-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55072-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:47:29Z","timestamp":1785800849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55072-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["55072"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-55072-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present investigation followed the guidelines of the Declaration of Helsinki 1964 and subsequent amendments or equivalent ethical standards. The study was designed and conducted in accordance with the ethical principles established by Imperial University College. Therefore, ethical approval was obtained from the Institutional Review Board Committee, Faculty of Pharmacy, Imperial University College. The present study data was completely anonymous without individual information. No personal information was obtained on the part of the community pharmacists for this survey. Community pharmacists informed consent was waived by the Institutional Review Board Committee, Faculty of Pharmacy, Imperial University College. as the data contains no individually identifying information.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23954"}}